---

---

•

Advanced programs designed to establish Saphyr as the leading platform for cytogenetics laboratories and replace potentially outdated technologies such as fluorescence in-situ hybridization (FISH), karyotyping and microarrays. Bionano is currently conducting two studies that will evaluate patients for different hematologic malignancies and certain rare genetic diseases and compare the results obtained using Saphyr to those obtained using standard of care tests. These studies are designed to show that Saphyr provides equivalent results to standard of care methods in a simplified and more reliable workflow that is less susceptible to errors and test failures.

•	Announced a publication showing that scientists at leading Chinese academic medical centers, together with Berry Genomics, a leading provider of pre-natal diagnostic tests in China, used Saphyr to correctly diagnose patients with facioscapulohumeral muscular dystrophy (FSHD). The publication showed that Saphyr can offer an improvement in workflow, provide highly

---

•

Announced the publication of the largest study of human genomes using Saphyr, which further demonstrated the utility of Saphyr’s technology in detecting structural variation. In the study, UCSF, Drexel University and The Chinese University of Hong Kong used Saphyr to analyze structural variation in 154 human samples, which had been previously analyzed with Illumina sequencing in the 1000 Genomes Project, and revealed never-before-seen structural variations. Bionano optical mapping identified 8.5 times more large insertions and 35% more large deletions than reported by the 1000 Genomes Project using Illumina sequencing.

•

Announced the publication of the Human Genome Structural Variation Consortium study, which found Saphyr to be essential for the comprehensive and efficient detection of structural variations. The study showed that most large structural variations detected by Saphyr were undetected by other technologies, including Illumina and PacBio systems. For example, for insertions larger than 10,000 bp, which is the size range where most clinically relevant genomic variations are found, Saphyr detected more events than all other genomic methods combined. The publication highlights the unique capability of Saphyr to comprehensively detect structural variations and enable the identification of their human disease associations. These detection capabilities are some of the drivers of the rapid increase in adoption of Saphyr to transform traditional cytogenetics into digital cytogenetics.

•	Launched new capabilities of the Saphyr system designed to significantly improve cost effectiveness, speed and ease of use for digital cytogenetics, which included:

•	a new version of the Saphyr Chip as well as a dual-cartridge capability that allows customers to process up to 42 whole human genomes per week;

•	a new sample preparation kit that enables customers to process up to six patient samples in less than four hours, compared to 48 hours for its predecessor, and offers lower cost on a per-sample basis, automatable protocol, faster run times and higher data quality.

---

•

Announced a new data analysis pipeline designed for analysis of complex, heterogeneous cancer samples and samples with germline mosaicism. All major types of structural variation can be detected with more than 80% sensitivity when present in just 5% allele fraction, while translocations and inversions can be detected with more than 90% sensitivity at this low frequency. Bionano and early-access users have successfully applied this workflow to various cancer samples, including leukemia, breast, ovarian, prostate, pancreatic, among others.

•	Entered into financing agreements totaling $41.5 million in debt and equity commitments from affiliates of Innovatus Capital Partners, LLC, East West Bank and Aspire Capital Fund, LLC.

•	North America revenue decreased by $0.2 million, or 19%;

•	EMEIA revenue increased by $0.8 million, or 826%; and

•	Asia Pacific revenue decreased by $0.5 million, or 85%.

---

---

---

---

---